Sandu Pharmaceuticals Ltd
Incorporated in 1985, Sandu Pharmaceuticals
Ltd is a manufacturer of Ayurvedic Medicines.[1]
- Market Cap ₹ 31.0 Cr.
- Current Price ₹ 32.0
- High / Low ₹ 58.8 / 30.6
- Stock P/E 20.0
- Book Value ₹ 43.5
- Dividend Yield 2.50 %
- ROCE 5.47 %
- ROE 3.75 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.74 times its book value
- Company has been maintaining a healthy dividend payout of 34.3%
Cons
- Promoter holding has decreased over last quarter: -5.11%
- Promoter holding is low: 37.8%
- Company has a low return on equity of 3.80% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 65.50 | 65.35 | 67.28 | 67.19 | |
| 62.62 | 62.87 | 64.98 | 64.43 | |
| Operating Profit | 2.88 | 2.48 | 2.30 | 2.76 |
| OPM % | 4.40% | 3.79% | 3.42% | 4.11% |
| 0.08 | 0.33 | 0.42 | 0.17 | |
| Interest | 0.11 | 0.08 | 0.06 | 0.10 |
| Depreciation | 0.53 | 0.52 | 0.58 | 0.67 |
| Profit before tax | 2.32 | 2.21 | 2.08 | 2.16 |
| Tax % | 31.47% | 31.22% | 29.33% | 28.24% |
| 1.59 | 1.52 | 1.46 | 1.55 | |
| EPS in Rs | 1.80 | 1.57 | 1.51 | 1.60 |
| Dividend Payout % | 41.56% | 0.00% | 52.93% | 49.86% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -1% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | -15% |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 4% |
| Last Year: | 4% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 8.81 | 9.66 | 9.66 | 9.66 |
| Reserves | 27.66 | 29.58 | 30.93 | 32.36 |
| 0.00 | 0.00 | 0.00 | 0.00 | |
| 12.81 | 14.93 | 11.82 | 13.71 | |
| Total Liabilities | 49.28 | 54.17 | 52.41 | 55.73 |
| 16.00 | 16.62 | 17.88 | 18.15 | |
| CWIP | 0.48 | 0.42 | 0.00 | 0.00 |
| Investments | 9.11 | 9.65 | 10.42 | 11.22 |
| 23.69 | 27.48 | 24.11 | 26.36 | |
| Total Assets | 49.28 | 54.17 | 52.41 | 55.73 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0.95 | 0.22 | 0.76 | 0.95 | |
| -5.47 | 0.54 | -1.31 | -0.19 | |
| 0.93 | 0.58 | -0.72 | -0.46 | |
| Net Cash Flow | -3.59 | 1.34 | -1.27 | 0.30 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 22.23 | 26.75 | 26.42 | 25.86 |
| Inventory Days | 115.06 | 167.70 | 137.28 | 160.90 |
| Days Payable | 69.63 | 98.30 | 47.07 | 51.05 |
| Cash Conversion Cycle | 67.67 | 96.15 | 116.63 | 135.70 |
| Working Capital Days | 42.41 | 52.33 | 56.75 | 62.80 |
| ROCE % | 6.05% | 5.36% | 5.47% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Electricity Purchased Units ・Standalone data |
|
|||||||||||
| Fuel Consumed - Diesel Liters ・Standalone data |
||||||||||||
| Median Remuneration of Employees INR ・Standalone data |
||||||||||||
| Number of Permanent Employees Count ・Standalone data |
||||||||||||
| Fuel Consumed - LSHS kg ・Standalone data |
||||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Feb - Newspaper publication inrespect of opening of special window for transfer and dematerialisation of shares
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Feb - Newspaper Publication inrespect of Unaudited Financials for the Q ended 31.12.2025
-
Statement Of Deviation And Variation For The Q Ended 31.12.2025
6 Feb - No deviation statement for three preferential raises: Rs2,63,79,653; Rs1,38,05,408; Rs1,31,94,934.
- Unaudited Financials For Quarter And Period Ended 31St December 2025 6 Feb
-
Board Meeting Outcome for Outcome Of The Board Meeting
6 Feb - Board approved unaudited standalone results for quarter/nine months ended 31-Dec-2025; limited review by Dileep & Prithvi.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
SPL is engaged in the business of manufacturing and trading of Ayurveda based medicines under the brand name SANDU